SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-076400
Filing Date
2024-06-21
Accepted
2024-06-21 18:12:53
Documents
1
Period of Report
2024-06-21

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 6392
  Complete submission text file 0000950170-24-076400.txt   7866
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39661 | Film No.: 241061639

Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Issuer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)